Filing Analysis
Pulmonx Corporation announced its financial results for the second fiscal quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release issued on July 29, 2026.
📋 Key Facts
- Reporting period: Second fiscal quarter ended June 30, 2026.
- Filing date: July 29, 2026.
- The filing includes a press release titled 'Pulmonx Reports Second Quarter 2026 Financial Results' as Exhibit 99.1.
Pulmonx Corporation reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. Stockholders elected three Class III directors, ratified the appointment of BDO USA, P.C. as the independent auditor, and approved executive compensation on an advisory basis.
📋 Key Facts
- Annual Meeting held on June 4, 2026, with 77.29% of outstanding shares (32,645,270 shares) represented.
- Elected Class III directors: Thomas W. Burns, Georgia Garinois-Melenikiotou, and Dana G. Mead, Jr.
- BDO USA, P.C. ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive compensation approved on a non-binding advisory basis with 17,196,362 votes in favor.
Pulmonx Corporation reported its financial results for the first fiscal quarter ended March 31, 2026. The announcement was made via a press release on April 29, 2026, and furnished to the SEC under Item 2.02.
📋 Key Facts
- The company reported financial results for the first quarter of 2026 on April 29, 2026.
- The reporting period for the results ended on March 31, 2026.
- The filing includes Exhibit 99.1, which is the full press release titled 'Pulmonx Reports First Quarter 2026 Financial Results'.
- The report was signed by Derrick Sung, Ph.D., who serves as both Chief Operating Officer and Chief Financial Officer.
Pulmonx Corporation entered into a $60 million senior secured term loan facility with Perceptive Credit Holdings, drawing an initial $40 million to refinance existing debt. The agreement includes revenue-based milestones for additional funding and the issuance of 1,000,000 warrants to the lender.
🚩 Red Flags
- High cost of capital with a minimum interest rate of 10.75% plus fees.
- Revenue-based covenants and milestones create pressure on commercial performance.
- Dilutive warrant issuance of 1,000,000 shares with potential for more upon future draws.
- Significant prepayment penalties ranging from 2% to 10% within the first four years.
📋 Key Facts
- Initial borrowing of $40.0 million on March 2, 2026, with up to $20.0 million additional available in two tranches based on revenue milestones ($92.5M and $100M TTM).
- Interest rate is set at 1-month SOFR (minimum 3.75%) plus a 7.00% margin, with a PIK option for 2.00% of the margin for the first 36 months.
- The facility matures on March 2, 2031, and carries a minimum liquidity covenant of $4.0 million.
- Issued 1,000,000 warrants to Perceptive with an exercise price of $1.92 per share (25% premium to 10-day VWAP).
- Proceeds were used to repay and terminate the existing CIBC Credit Agreement without early termination penalties.
Pulmonx Corporation reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The announcement was made via a press release furnished under Item 2.02.
📋 Key Facts
- Financial results cover the fourth quarter and full year ended December 31, 2025
- The report was filed and dated March 4, 2026
- The filing includes Exhibit 99.1, which is the official press release of the earnings
- The document was signed by Derrick Sung, Ph.D., who serves as both Chief Operating Officer and Chief Financial Officer
Pulmonx Corporation filed an 8-K to announce its third fiscal quarter financial results for the period ended September 30, 2025. The filing serves as a formal transmission of the company's quarterly earnings press release.
📋 Key Facts
- Reporting date: November 12, 2025
- Fiscal period covered: Third quarter ended September 30, 2025
- The filing includes Exhibit 99.1 containing the official earnings press release.
- Signed by Derrick Sung, Chief Financial Officer.
Pulmonx Corporation announced a major leadership overhaul effective October 27, 2025, involving the simultaneous resignation of both the CEO and CFO. The company has appointed Glendon E. French as new CEO and Derrick Sung, Ph.D., as COO/CFO to manage the transition.
🚩 Red Flags
- Simultaneous departure of both CEO and CFO is a major governance red flag often associated with internal instability or financial scrutiny.
- Performance-based equity vesting for new executives is tied to a $4.00 stock price, implying current trading may be significantly below this threshold.
- Significant cash outflows related to separation agreements ($947,625 total for CEO/CFO severance).
📋 Key Facts
- CEO Steven S. Williamson resigned effective October 27, 2025; receiving $600,000 severance over 12 months plus COBRA coverage.
- CFO Mehul Joshi resigned effective October 27, 2025; receiving $347,625 severance over 9 months plus COBRA coverage.
- Glendon E. French appointed CEO effective October 27, 2025; includes RSU and PSU grants with a performance condition tied to a $4.00 stock price.
- Derrick Sung, Ph.D., appointed COO and CFO effective November 3, 2025; includes significant equity inducements per Nasdaq Rule 5635(c)(4).
- Both new executive equity grants (RSU/PSU) contain performance conditions requiring the stock to trade above $4.00 for 60 consecutive trading days.
Pulmonx Corporation announced its financial results for the second fiscal quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release issued on July 30, 2025.
📋 Key Facts
- Reported date: July 30, 2025
- Period covered: Second fiscal quarter ended June 30, 2025
- The filing includes a press release titled 'Pulmonx Reports Second Quarter 2025 Financial Results' as Exhibit 99.1.
Pulmonx Corporation held its 2025 Annual Meeting of Stockholders on May 22, 2025. The company successfully elected three Class II directors and ratified BDO USA, P.C. as its independent auditor for the 2025 fiscal year.
📋 Key Facts
- Annual Meeting held on May 22, 2025.
- Quorum reached with 33,322,365 shares present (82.79% of outstanding common stock).
- Three Class II directors elected: Richard M. Ferrari, Daniel P. Florin, and Steven S. Williamson.
- BDO USA, P.C. ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Non-binding advisory vote on executive compensation was approved.
Pulmonx Corporation announced its financial results for the first fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of the quarterly earnings release.
📋 Key Facts
- Reporting period: First fiscal quarter ended March 31, 2025.
- Announcement date: April 30, 2025.
- The company issued a press release titled 'Pulmonx Reports First Quarter 2025 Financial Results' as Exhibit 99.1.
Pulmonx Corporation issued an 8-K to announce its financial results for the fourth fiscal quarter and full year ended December 31, 2024. The filing serves as a formal announcement of record performance via an attached press release.
📋 Key Facts
- Reported date: February 19, 2025
- Period covered: Fourth fiscal quarter and full year ended December 31, 2024
- The company describes the results as 'Record Fourth Quarter and Full Year 2024 Financial Results' in the attached press release.
- Filed under Item 2.02 (Results of Operations and Financial Condition).
Pulmonx Corporation filed an 8-K to announce its third fiscal quarter 2024 financial results. The filing serves as a formal notice that the company's quarterly earnings press release has been issued.
📋 Key Facts
- Reporting period: Third fiscal quarter ended September 30, 2024.
- Filing date: October 30, 2024.
- The filing includes a press release titled 'Pulmonx Reports Third Quarter 2024 Financial Results' as Exhibit 99.1.
Pulmonx Corporation issued an 8-K to announce its second fiscal quarter 2024 financial results. The filing serves as a formal notification that the company's earnings press release is being furnished under Item 2.02.
📋 Key Facts
- Reporting period: Second fiscal quarter ended June 30, 2024.
- Filing date: July 31, 2024.
- The filing includes a press release titled 'Pulmonx Reports Second Quarter 2024 Financial Results' as Exhibit 99.1.
Pulmonx Corporation entered into two lease amendments to expand its office space in Redwood City, California. The agreements involve extending existing leases and adding expansion premises through 2035.
🚩 Red Flags
- Long-term lease commitments through 2035 increase fixed operating expenses.
📋 Key Facts
- Entered into Third Amendment to Office Lease with HCP LS Redwood City, LLC on May 17, 2024.
- Entered into Third Amendment to Sublease Agreement with Genomic Health, Inc. on May 17, 2024.
- Existing Premises lease extended for 10 years (August 1, 2025 – July 31, 2035) at $113,118.60/month with a 3.5% annual increase.
- Expansion Premises sublease begins March 1, 2025 through May 31, 2028 at $92,177.10/month with ~3% annual increase.
- Direct lease for Expansion Premises starts June 1, 2028 and expires July 31, 2035 at $107,329.50/month with a 3.5% annual increase.
- Includes two options to extend the entire Leased Premises for five years each.
Pulmonx Corporation held its 2024 Annual Meeting of Stockholders on May 16, 2024. The meeting resulted in the election of two Class I directors and the ratification of BDO USA, P.C. as independent auditors.
📋 Key Facts
- Annual Meeting held on May 16, 2024.
- 88.59% of outstanding common stock (34,386,725 shares) was represented at the meeting.
- Glendon E. French and Tiffany Sullivan were elected to Class I director positions until 2027.
- BDO USA, P.C. was ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Stockholders approved executive compensation on a non-binding advisory basis.
Pulmonx Corporation issued an 8-K to announce its financial results for the first fiscal quarter ended March 31, 2024. The filing serves as a formal mechanism to furnish quarterly earnings data via a press release.
📋 Key Facts
- Reporting period: First fiscal quarter ended March 31, 2024.
- Filing date: May 1, 2024.
- The filing includes Exhibit 99.1 containing the 'Pulmonx Reports First Quarter 2024 Financial Results' press release.
Pulmonx Corporation announced the appointment of Mehul Joshi as Chief Financial Officer and Principal Financial and Accounting Officer, effective April 3, 2024. This transition involves the return of interim CFO John McKune to his previous role as VP Finance and Corporate Controller.
🚩 Red Flags
- Clawback provisions on the sign-on bonus indicate company protection against early departure, though standard in many executive contracts.
📋 Key Facts
- Mehul Joshi appointed CFO/Principal Financial and Accounting Officer effective April 3, 2024.
- Joshi's compensation includes a $450,000 annual base salary and a target bonus of 50% ($225,000).
- Initial equity grants include $1,375,000 in stock options and $1,350,000 in Restricted Stock Units (RSUs), vesting over four years.
- A sign-on bonus of $200,000 was granted with a clawback provision if terminated for cause or resigning within two years.
- John McKune will transition from Interim CFO back to VP Finance and Corporate Controller.
Pulmonx Corporation filed an 8-K to announce its financial results for the fourth fiscal quarter and full year ended December 31, 2023. The filing serves as a formal mechanism to furnish quarterly earnings data via a press release.
📋 Key Facts
- Report date: February 21, 2024
- Reporting period: Fourth fiscal quarter and full year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the press release 'Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results'
- Interim CFO John McKune signed the report
Pulmonx Corporation announced a leadership transition involving the resignation of CEO Glendon E. French and the appointment of Steven S. Williamson as the new President and CEO, effective March 15, 2024.
🚩 Red Flags
- Sudden departure of a sitting CEO (though transition is phased).
- Reduction in board size following a director's decision not to stand for re-election.
📋 Key Facts
- CEO Glendon E. French resigned on February 20, 2024; effective transition date is March 15, 2024.
- Mr. French will serve as Senior Advisor until May 1, 2024, and remain a Class I director.
- Steven S. Williamson appointed President and CEO, effective March 15, 2024.
- Williamson's compensation includes an annual base salary of $580,000 plus a 75% target bonus.
- Inducement grants for the new CEO include $2.5M in stock options and $2.5M in RSUs vesting over four years.
- Director Alissa Hsu Lynch will not stand for re-election at the 2024 annual meeting, reducing board size to eight directors.